Emerging therapy

Medicinal mushrooms and nootropics

Lion's mane (Hericium erinaceus), reishi, cordyceps, citicoline, piracetam, psilocybin

A research band worth watching, and a supplement shelf to approach carefully. Some of these compounds have real laboratory interest; almost none has been tested in children with neurological conditions.

Where it stands, condition by condition

The same therapy can be well supported for one problem and completely untested for another. This is the single most common place families are misled.

What it is

A loose group of fungal extracts and nootropic compounds sold on the claim that they support nerve growth, cognition or recovery.

Lion's mane attracts the most interest. Hericenones and erinacines isolated from it stimulate nerve growth factor in cell and animal work, which is a genuinely interesting finding and the reason it appears in research discussions at all.

Citicoline and the racetams are pharmaceutical compounds rather than supplements in several countries — citicoline in particular has been studied for decades, mostly in adults.

Everything else in the aisle — blends, powders, “mushroom complexes” — belongs to a different category, where the product is a consumer good and the claim is marketing.

How it is meant to work

The lion's mane rationale is specific: if a compound increases nerve growth factor, it might support neuronal survival and plasticity.

Two problems sit between that and a child. The compounds studied in the laboratory are isolated fractions, not the powder in a capsule; and how much reaches the brain after swallowing a supplement is largely unknown.

Citicoline's proposed mechanism concerns cell-membrane phospholipid synthesis, which is plausible and has nonetheless produced inconsistent clinical results in adults.

What has actually been tested

• For lion's mane there are small adult studies on cognition and mood, of variable quality. In children with cerebral palsy, autism or epilepsy there is essentially nothing.
• Citicoline has been through sizeable adult trials with disappointing or mixed results in acute stroke; enthusiasm has cooled rather than grown.
• Piracetam has a long clinical history in some countries and a thin evidence base behind it, particularly in children.
• Psilocybin trials in adult depression and end-of-life distress are well conducted and completely irrelevant to a child with cerebral palsy. Its presence in the same conversation is a marketing artefact.
• Across the whole group, the reason evidence is absent is mostly that these products are sold as supplements, and supplements do not have to prove anything before sale.

What we still do not know

• Whether any of these compounds crosses into the brain in meaningful amounts at the doses sold.
• What a given capsule actually contains — fungal supplement analyses frequently find mismatches between label and content.
• Safety during long-term use in a developing brain.
• Interactions, particularly with antiseizure medication, which almost no product labels address.

Risks and costs

• Interactions are the serious one. Supplements can alter the blood levels of antiseizure medicines, and a child whose seizures worsen after a new capsule is a scenario clinicians see.
• Allergic reactions to fungal products, which are not rare.
• Unknown contents and contamination in unregulated products.
• Cost and distraction — an affordable-looking monthly purchase that quietly replaces attention to sleep, nutrition and therapy.

Questions to ask before you agree

1. Does this interact with my child's antiseizure medication, and who checked?
2. What is the evidence in children, as opposed to adults or laboratory models?
3. What exactly is in it, in what quantity, and who verified that?
4. What would tell us it is not working, and when do we stop?

More in this section